Conference Coverage

Luca Richeldi, MD, PhD
University of Southampton

Dr. Richeldi addresses the following questions:

  • What developments in treatment of IPF were presented at the PFF annual meeting?
  • What is the role of patient registries in IPF?
  • Have there been any clinical studies of pirfenidone combined with nintedanib?




Related Videos

Biomarkers for IPF

Conference Coverage

Naftali Kaminski, MD
Yale School of Medicine

Dr. Kaminski addresses the following questions:

  • Which biomarkers have been investigated for IPF?
  • Are there biomarkers that help diagnosis of IPF?
  • Are there biomarkers for prognosis or monitoring of IPF?
  • Can biomarkers influence disease management choices?
  • Is there a role for genetic testing in IPF?

Conference Coverage

Andrew M. Tager, MD
Harvard Medical School

Dr. Tager addresses the following questions:

  • How do nintedanib and pirfenidone work?
  • Which targets are being investigated in the search for new drugs?
  • Which drug candidates might emerge in the near future?
  • Are there drugs for other indications that might be useful for IPF?